Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The changes in body composition are early adverse effects of androgen deprivation therapy (ADT); however, their prognostic impact remains unclear in prostate cancer. This study aimed to evaluate the association between body composition changes and survival in patients with high-risk prostate cancer. We measured the skeletal muscle index (SMI) and total adipose tissue index (TATI) at the L3 vertebral level using computed tomography at baseline and within one year after initiating ADT in 125 patients with high-risk prostate cancer treated with radiotherapy and ADT between 2008 and 2018. Non-cancer mortality predictors were identified using Cox regression models. The median follow-up was 49 months. Patients experienced an average SMI loss of 5.5% over 180 days (95% confidence interval: -7.0 to -4.0; p <0.001) and TATI gain of 12.6% over 180 days (95% confidence interval: 9.0 to 16.2; p <0.001). Body mass index changes were highly and weakly correlated with changes in TATI and SMI, respectively (Spearman ρ for TATI, 0.78, p <0.001; ρ for SMI, 0.27, p =0.003). As a continuous variable, each 1% decrease in SMI was independently associated with a 9% increase in the risk of non-cancer mortality (hazard ratio: 1.09; p =0.007). Moreover, the risk of non-cancer mortality increased 5.6-fold in patients with SMI loss ≥5% compared to those with unchanged SMI (hazard ratio: 5.60; p =0.03). Body mass index and TATI were not associated with non-cancer mortality. Muscle loss during ADT is occult, independent of weight change, and independently associated with increased non-cancer mortality in patients with high-risk prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Baracos, V. E., & Arribas, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx810 · Cited by 362
Naumann, P., Eberlein, J., Farnia, B., Liermann, J., Hackert, T., Debus, J., & Combs, S. E. (2019) · Cancers · doi:10.3390/cancers11111655 · Cited by 54
Research works printed but not linked: 40
- Nabid, 2018, Duration of Androgen Deprivation Therapy in High-Risk Prostate Cancer: A Randomized Phase III Trial, Eur Urol, 74, 10.1016/j.eururo.2018.06.018 · DOI · Paper page
- Lawton, 2017, Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202, Int J Radiat Oncol Biol Phys, 98, 296, 10.1016/j.ijrobp.2017.02.004 · DOI
- Saylor, 2013, Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer, J Urol, 189, S34, 10.1016/j.juro.2012.11.017 · DOI · Paper page
- Marvaso, 2021, Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches, Front Oncol, 11, 10.3389/fonc.2021.732766 · DOI
- Lee, 2005, Changes in Bone Mineral Density and Body Composition During Initial and Long-Term Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Carcinoma, Cancer, 104, 10.1002/cncr.21381 · DOI · Paper page
- Smith, 2012, Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer, J Clin Oncol, 30, 10.1200/JCO.2011.38.8850 · DOI · Paper page
- Nguyen, 2015, Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them, Eur Urol, 67, 10.1016/j.eururo.2014.07.010 · DOI · Paper page
- Owen, 2019, The Clinical Relevance of Adiposity When Assessing Muscle Health in Men Treated With Androgen Deprivation for Prostate Cancer, J Cachexia Sarcopenia Muscle, 10, 10.1002/jcsm.12446 · DOI
- Palumbo, 2021, Changes in Body Composition and Lipid Profile in Prostate Cancer Patients Without Bone Metastases Given Degarelix Treatment: The BLADE Prospective Cohort Study, Prostate Cancer Prostatic Dis, 24, 10.1038/s41391-021-00345-0 · DOI
- Suriano, 2020, Gut Microbiota and Regulation of Myokine-Adipokine Function, Curr Opin Pharmacol, 52, 9, 10.1016/j.coph.2020.03.006 · DOI
- McDonald, 2017, CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men With Prostate Cancer, Radiology, 282, 10.1148/radiol.2016160626 · DOI
- Huang, 2020, Prognostic Value of Muscle Measurement Using the Standardized Phase of Computed Tomography in Patients With Advanced Ovarian Cancer, Nutrition, 72, 110642, 10.1016/j.nut.2019.110642 · DOI
- Brown, 2018, The Evolution of Body Composition in Oncology-Epidemiology, Clinical Trials, and the Future of Patient Care: Facts and Numbers, J Cachexia Sarcopenia Muscle, 9, 10.1002/jcsm.12379 · DOI · Paper page
- Lee, 2018, Skeletal Muscle Loss Is an Imaging Biomarker of Outcome After Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer, Clin Cancer Res, 24, 10.1158/1078-0432.CCR-18-0788 · DOI
- Lee, 2019, Muscle Radiodensity Loss During Cancer Therapy Is Predictive for Poor Survival in Advanced Endometrial Cancer, J Cachexia Sarcopenia Muscle, 10, 10.1002/jcsm.12440 · DOI
- van Dijk, 2017, Low Skeletal Muscle Radiation Attenuation and Visceral Adiposity Are Associated With Overall Survival and Surgical Site Infections in Patients With Pancreatic Cancer, J Cachexia Sarcopenia Muscle, 8, 10.1002/jcsm.12155 · DOI · Paper page
- Huang, 2020, Muscle Loss During Primary Debulking Surgery and Chemotherapy Predicts Poor Survival in Advanced-Stage Ovarian Cancer, J Cachexia Sarcopenia Muscle, 11, 10.1002/jcsm.12524 · DOI
- Lee, 2021, Progressive Muscle Loss Is an Independent Predictor for Survival in Locally Advanced Oral Cavity Cancer: A Longitudinal Study, Radiother Oncol, 158, 10.1016/j.radonc.2021.02.014 · doi:10.1016/j.radonc.2021.02.014
- Kays, 2018, Three Cachexia Phenotypes and the Impact of Fat-Only Loss on Survival in FOLFIRINOX Therapy for Pancreatic Cancer, J Cachexia Sarcopenia Muscle, 9, 10.1002/jcsm.12307 · DOI
- Hua, 2021, Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy, Front Oncol, 11, 10.3389/fonc.2021.625534 · doi:10.3389/fonc.2021.625534
- Lee, 2021, Association of Patient-Reported Outcomes and Nutrition With Body Composition in Women With Gynecologic Cancer Undergoing Post-Operative Pelvic Radiotherapy: An Observational Study, Nutrients, 13, 2629, 10.3390/nu13082629 · DOI
- Caan, 2018, The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint, Cancer Res, 78, 10.1158/0008-5472.CAN-17-3287 · DOI · Paper page
- Lee, 2020, Muscle Loss After Chemoradiotherapy as a Biomarker of Distant Failures in Locally Advanced Cervical Cancer, Cancers (Basel), 12, 595, 10.3390/cancers12030595 · DOI
- Lee, 2018, The Effect of Body Mass Index and Weight Change on Late Gastrointestinal Toxicity in Locally Advanced Cervical Cancer Treated With Intensity-Modulated Radiotherapy, Int J Gynecol Cancer, 28, 10.1097/IGC.0000000000001312 · doi:10.1097/igc.0000000000001312
- Faron, 2020, Body Composition Analysis Using CT and MRI: Intra-Individual Intermodal Comparison of Muscle Mass and Myosteatosis, Sci Rep, 10, 11765, 10.1038/s41598-020-68797-3 · DOI · Paper page
- Newton, 2020, Timing of Exercise for Muscle Strength and Physical Function in Men Initiating ADT for Prostate Cancer, Prostate Cancer Prostatic Dis, 23, 10.1038/s41391-019-0200-z · DOI
- Di Maso, 2021, Adherence to Mediterranean Diet, Physical Activity and Survival After Prostate Cancer Diagnosis, Nutrients, 13, 243, 10.3390/nu13010243 · DOI
- Edmunds, 2020, The Role of Exercise in the Management of Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: A Rapid Review, Support Care Cancer, 28, 10.1007/s00520-020-05637-0 · DOI
- Bylow, 2008, Falls and Physical Performance Deficits in Older Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy, Urology, 72, 10.1016/j.urology.2008.03.032 · DOI · Paper page
- Alibhai, 2010, Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer, J Clin Oncol, 28, 10.1200/JCO.2010.29.8091 · DOI · Paper page
- Shahinian, 2005, Risk of Fracture After Androgen Deprivation for Prostate Cancer, N Engl J Med, 352, 10.1056/NEJMoa041943 · DOI · Paper page
- Sattar, 2021, Falls in Older Adults With Cancer: An Updated Systematic Review of Prevalence, Injurious Falls, and Impact on Cancer Treatment, Support Care Cancer, 29, 21, 10.1007/s00520-020-05619-2 · DOI
- Waterhouse, 2021, Vitamin D Supplementation and Risk of Falling: Outcomes From the Randomized, Placebo-Controlled D-Health Trial, J Cachexia Sarcopenia Muscle, 10.1002/jcsm.12759 · DOI
- Urquiza, 2020, Nutritional Status Is Associated With Function, Physical Performance and Falls in Older Adults Admitted to Geriatric Rehabilitation: A Retrospective Cohort Study, Nutrients, 12, 2855, 10.3390/nu12092855 · DOI
- Dautzenberg, 2021, Interventions for Preventing Falls and Fall-Related Fractures in Community-Dwelling Older Adults: A Systematic Review and Network Meta-Analysis, J Am Geriatr Soc, 10.1111/jgs.17375 · DOI · Paper page
- McCarthy, 2016, Diagnosis and Management of Vertebral Compression Fractures, Am Fam Physician, 94, 44
- Wilson, 2021, Using Exercise and Nutrition to Alter Fat and Lean Mass in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review, Nutrients, 13, 1664, 10.3390/nu13051664 · DOI
- Finkelstein, 2020, Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa318 · DOI
- Klotz, 2015, Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT, J Clin Oncol, 33, 10.1200/JCO.2014.58.2973 · DOI · Paper page
- Crawford, 2019, Androgen-Targeted Therapy in Men With Prostate Cancer: Evolving Practice and Future Considerations, Prostate Cancer Prostatic Dis, 22, 24, 10.1038/s41391-018-0079-0 · DOI · Paper page
Metadata
- Authors
- Chiang, P.-K., Tsai, W.-K., Chiu, A. W.-H., Lin, J.-B., Yang, F.-Y., & Lee, J.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2021-09-17
- Volume
- 11
- ISSN
- 2234-943X
- Cited by
- 35
- References
- 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.